Selected articles
Articles for label Pospíšková Markéta are displayed.. Show all articles
Possibilities of biological treatment of head and neck cancers
06/2018 MUDr. Markéta Pospíšková
Tumors of the head and neck are among the world's most incidences of cancer. In the last decade there has been an increase in tumors associated with HPV infection and a decrease in the incidence of tumors associated with smoking and alcohol abuse. Despite the awareness, there are still 60% of patients in locoregional advanced stages and 12 % of patients have distant metastasis at the time of diagnosis. The basis of treatment is a multidisciplinary approach. Thanks to new knowledge about tumor biology, which has brought new therapeutic options (antibodies, immunotherapy), generalized and relapsing cancers have improved survival.
ENTIRE ARTICLE
Tumors of the head and neck are among the world's most incidences of cancer. In the last decade there has been an increase in tumors associated with HPV infection and a decrease in the incidence of tumors associated with smoking and alcohol abuse. Despite the awareness, there are still 60% of patients in locoregional advanced stages and 12 % of patients have distant metastasis at the time of diagnosis. The basis of treatment is a multidisciplinary approach. Thanks to new knowledge about tumor biology, which has brought new therapeutic options (antibodies, immunotherapy), generalized and relapsing cancers have improved survival.
Long‐term treatment of prostate cancer with a well‐chosen treatment algorithm while maintaining a good quality of life
02/2018 MUDr. Adam Guňka, MUDr. Markéta Pospíšková, MUDr. Milan Kohoutek
Prostate cancer is after lung cancer the most common type of malignant tumor in the male population worldwide. We can gradually decrease the number of lung patients by educating the population and using anti-smoking campaigns and hopefully the incidence and prevalence of the illness can be changed in the future. The probability of prostate cancer rises with age. Despite frequent occurrence this disease is not one of the diagnoses with poor prognosis depending on incidence. 80% of the patients are diagnosed with the disease which is not locally advanced and there is approximately 95% survival rate that the patients would live up to five years. This is not only thanks to early diagnosis but also thanks to new medications available in clinical practice. In Hormone-Dependent Prostate Cancer, the development of hormone-resistant disease can be delayed by an average of three years by the luteinizing hormone-releasing hormone analog. Subsequently, the inclusion of androgen receptor targeted agents in the therapeutic algorithm of cast rationally-resistant prostate cancer has brought great advances in the treatment. Also, we cannot forget about the chemotherapy systematic treatment for generalized carcinoma where, for example, the Tax 327 study in 2004 showed a significantly longer survival of docetaxel-treated patients in combination with prednisone against mitoxantrone with prednisone.
ENTIRE ARTICLE
Prostate cancer is after lung cancer the most common type of malignant tumor in the male population worldwide. We can gradually decrease the number of lung patients by educating the population and using anti-smoking campaigns and hopefully the incidence and prevalence of the illness can be changed in the future. The probability of prostate cancer rises with age. Despite frequent occurrence this disease is not one of the diagnoses with poor prognosis depending on incidence. 80% of the patients are diagnosed with the disease which is not locally advanced and there is approximately 95% survival rate that the patients would live up to five years. This is not only thanks to early diagnosis but also thanks to new medications available in clinical practice. In Hormone-Dependent Prostate Cancer, the development of hormone-resistant disease can be delayed by an average of three years by the luteinizing hormone-releasing hormone analog. Subsequently, the inclusion of androgen receptor targeted agents in the therapeutic algorithm of cast rationally-resistant prostate cancer has brought great advances in the treatment. Also, we cannot forget about the chemotherapy systematic treatment for generalized carcinoma where, for example, the Tax 327 study in 2004 showed a significantly longer survival of docetaxel-treated patients in combination with prednisone against mitoxantrone with prednisone.